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Multiple sclerosis (MS) and its animal model, 
experimental autoimmune encephalomyelitis 
(EAE), are demyelinating diseases of the central 
nervous system (CNS) mediated by autoreac-
tive T cells that penetrate through the blood–
brain barrier (BBB) into the brain parenchyma. 
These T cells initiate autoimmune responses 
against antigens in the myelin sheath of the 
CNS, including myelin basic protein or myelin 
oligodendrocyte protein (1). Thus, the recruit-
ment of autoreactive lymphocytes represents 
a crucial pathogenetic event in initiating CNS 
infl  ammation, and interfering with the homing 
of these cells may represent a feasible therapeu-
tic approach for both EAE and MS.
Lymphocyte extravasation requires a well-
coordinated sequence of adhesive and signal-
ing events, including selectin-mediated rolling, 
chemoattractant-induced integrin activation, 
integrin-dependent fi  rm adhesion, and the sub-
sequent transendothelial migration (2). During 
adhesion and transmigration, integrins of the 
β1 and β2 family, such as VLA-4 (α4β1) or 
LFA-1 (αLβ2), bind to their endothelial counter-
receptors vascular cell adhesion molecule 
(VCAM)-1 and intercellular adhesion molecule 
(ICAM)-1, respectively. Numerous studies 
have shown that adhesion of lymphocytes to 
infl   amed brain vessels during EAE is mainly 
mediated by the VLA-4–VCAM-1 system 
(3, 4), although there is also evidence pointing 
to the role of the LFA-1–ICAM-1 interaction 
(5, 6). Recent studies indicated that both sys-
tems may have a distinct contribution in the 
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Multiple sclerosis (MS) is a devastating infl  ammatory disorder of the central nervous system 
(CNS). A major hallmark of MS is the infi  ltration of T cells reactive against myelin compo-
nents. T cell infi  ltration is mediated by the interaction of integrins of the 𝗃1 and 𝗃2 family 
expressed by lymphocytes with their endothelial counter-receptors, vascular cell adhesion 
molecule 1 and intercellular adhesion molecule (ICAM)-1, respectively. We have reported 
previously that extracellular adherence protein (Eap) of Staphylococcus aureus exerts anti-
infl  ammatory activities by interacting with ICAM-1 and blocking 𝗃2-integrin–dependent 
neutrophil recruitment. Here, we report that Eap inhibits experimental autoimmune enceph-
alomyelitis (EAE) in mice. In vitro, Eap reduced adhesion of peripheral blood T cells to 
immobilized ICAM-1 as well as their adhesion and transmigration of TNF-activated human 
endothelium under static and shear fl  ow conditions. These inhibitory effects were corrobo-
rated in two mouse models of infl  ammation. In a delayed-type hypersensitivity model, both 
T cell infi  ltration and the corresponding tissue edema were signifi  cantly reduced by Eap. 
In addition, Eap administration prevented the development of EAE and markedly decreased 
infi  ltration of infl  ammatory cells into the CNS. Strikingly, intervention with Eap after the 
onset of EAE suppressed the disease. Collectively, our fi  ndings indicate that Eap represents 
an attractive treatment for autoimmune neuroinfl  ammatory disorders such as MS.
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recruitment of encephalitogenic T cells. Although the 
VLA-4–VCAM-1 interaction predominantly mediates the 
initial adhesion to the infl  amed vessels, LFA-1–ICAM-1 are 
engaged in the subsequent transendothelial migration of 
T cells (7, 8).
To date, therapeutic approaches targeting adhesion mol-
ecules have focused predominantly on the blockade of the 
VLA-4–VCAM-1 system (9). An antibody to VLA-4 that 
ameliorated EAE in mice was humanized (natalizumab) and 
demonstrated encouraging clinical effi   cacy for the treatment 
of patients with relapsing forms of multiple sclerosis. How-
ever, a few cases of fatal progressive multifocal leukoenceph-
alopathy attributed to natalizumab prompted its withdrawal 
(9). Thus, the need for other adhesion molecule–based thera-
pies is emerging. In contrast with the VLA-4–VCAM-1 sys-
tem, only a few studies have addressed the role of the 
LFA-1–ICAM-1 system as a target in EAE, although ICAM-
1 is clearly up-regulated in EAE and MS, and serum levels of 
soluble ICAM-1 were found to be elevated in MS patients 
with clinically symptomatic disease (5, 6, 10).
Extracellular adherence protein (Eap), also designated 
MHC class II analogous protein (Map) or P70, is a secreted 
protein from Staphylococcus aureus. Eap has a very broad rep-
ertoire of binding interactions to host extracellular matrix 
components (11, 12). Recently, we demonstrated a mecha-
nism used by S. aureus to escape the host immune system that 
was attributed to the very potent antiinfl  ammatory function 
of Eap. In particular, we found Eap to undergo a direct in-
teraction with ICAM-1 that resulted in the disruption of 
  integrin-dependent neutrophil–endothelial interactions (13). 
Strikingly, Eap was even more potent than blocking antibod-
ies against the β2-integrin receptors or against ICAM-1.
These observations prompted us to investigate whether 
Eap could be feasible to interfere with T cell–adhesive mech-
anisms in EAE. In the present study, we show that Eap inhib-
its the LFA-1–ICAM-1 interaction and the T cell–endothelial 
interactions in vitro and in vivo. Furthermore, administration 
of Eap not only prevented the development of EAE, but Eap 
treatment reverted the disease and repressed its progress after 
its onset. Thus, Eap may represent a promising new therapy 
for chronic infl  ammatory diseases such as EAE and MS.
RESULTS
Eap blocks adhesion of T cells to ICAM-1
We have previously shown that Eap interferes with the in-
teraction between ICAM-1 and its β2-integrin counter-
  receptors Mac-1 and LFA-1, thereby blocking neutrophil 
recruitment (13). To test whether Eap might interfere with 
T cell recruitment, we fi  rst examined the adhesion of peripheral 
blood T (PBT) cells to immobilized ICAM-1 and VCAM-1. 
Figure 1.  Eap inhibits T cell adhesion to ICAM-1. (A) The adhesion 
of T cells to immobilized ICAM-1 is shown in the absence (white bars) or 
presence of blocking mAb against VLA-4, mAb against LFA-1 (each at 
20 μg/ml), increasing concentrations of purifi  ed (gray bars), or recombi-
nant (black bars) Eap, or cationic BSA (20 μg/ml). (B) The adhesion of 
T cells to immobilized VCAM-1 is shown in the absence or presence of 
blocking mAb against VLA-4, mAb against LFA-1 (each at 20 μg/ml), puri-
fi  ed Eap, recombinant Eap, or cationic BSA (each at 20 μg/ml). Cell adhe-
sion is expressed relative to control (in the absence of competitor). Data 
are mean ± SD (n = 3) of a typical experiment; similar results were ob-
tained in three separate experiments. (C and D) Adhesion of 
T cells to immobilized ICAM-1 (C) or VCAM-1 (D) under laminar shear fl  ow 
conditions is shown in the absence (white bars) or presence of cationic 
BSA (diagonally striped bars), purifi  ed Eap (gray bars), recombinant Eap 
(black bars), or anti-LFA-1 mAb (dotted bars) (each at 20 μg/ml). Data are 
mean ± SEM, n = 3 separate experiments. *, P < 0.05. **, P < 0.01.JEM VOL. 203, April 17, 2006  987
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As shown in Fig. 1, the adhesion of PBT cells to immobilized 
ICAM-1 was mediated by LFA-1, whereas adhesion to 
VCAM-1 was dependent on β1-integrins. Under both static 
(Fig. 1, A and B) and physiologic fl  ow conditions (Fig. 1, C 
and D), both purifi  ed and recombinant Eap dose-dependently 
inhibited the adhesion of PBT cells to immobilized ICAM-1, 
whereas adhesion of PBT cells to VCAM-1 was not aff  ected 
in the presence of Eap. The inhibitory eff  ect of Eap on the 
adhesion of PBT cells to ICAM-1 was comparable to the 
  eff  ect of blocking mAb to LFA-1 (Fig. 1). As Eap is a cationic 
protein, we engaged cationic BSA as a negative control, 
which did not aff  ect LFA-1– or VLA-4–dependent adhesion 
to ICAM-1 or VCAM-1, respectively (Fig. 1).
Interference of Eap with T cell–endothelial cell interactions 
under static and physiologic fl  ow conditions
As Eap blocks the adhesion of PBT cells to ICAM-1, we 
  further determined whether Eap interferes with PBT cell–
endothelial cell interactions. Therefore, the adhesion of PBT 
cells to endothelial cells as well as the transmigration of PBT 
cells through endothelial cell monolayers was studied under 
static and physiologic fl  ow conditions. Under static condi-
tions, the adhesion of PBT cells to TNF-α–prestimulated en-
dothelial cells was mainly dependent on VLA-4, whereas the 
LFA-1–ICAM-1 system mediates a smaller portion of the 
T cell adhesion to endothelial cells under these conditions 
(Fig. 2 A). Both purifi   ed and recombinant Eap partially 
blocked adhesion of PBT cells to endothelial cells; the maxi-
mal inhibition observed was  35–40% and was comparable 
to the inhibition obtained with blocking mAb to LFA-1 (Fig. 
2 A). In contrast, transendothelial migration of PBT cells was 
predominantly mediated by the LFA-1–ICAM-1 interaction; 
in this case, both purifi  ed and recombinant Eap were more 
potent in blocking PBT cell transendothelial migration (Fig. 
2 B). As a negative control, cationic BSA did not infl  uence 
PBT cell adhesion or transmigration.
Because the PBT cell–endothelial cell interactions under 
physiologic fl  ow conditions simulate in vivo physiological 
shear fl  ow, we studied the eff  ect of Eap under defi  ned shear 
fl  ow in vitro (14, 15). As previously reported, PBT cell adhe-
sion to TNF-α–prestimulated endothelial cells under physio-
logic fl  ow in vitro is mainly dependent on the VLA-4–VCAM-1 
adhesion pathway and to a lesser extent on the LFA-1–
ICAM-1 pathway, whereas transmigration was primarily 
LFA-1–ICAM-1 dependent (7, 14, 16). Consistent with 
these prior observations, here we show that purifi  ed or re-
combinant Eap (data with recombinant Eap not shown) as 
well as blocking mAb to LFA-1 had no statistically signifi  cant 
eff  ect on adhesion of PBT cells to TNF-α–activated human 
umbilical vein endothelial cell (HUVEC) monolayers under 
fl  ow conditions (Fig. 3 A), whereas transendothelial migra-
tion was signifi  cantly blocked by Eap or mAb to LFA-1 (Fig. 
3 B). In contrast, no eff  ect of cationic BSA was observed. 
Collectively, these data (Figs. 1–3) indicate that Eap inter-
feres with the LFA-1–ICAM-1–dependent component of 
T cell–endothelial interaction pathway under both static and 
physiologic fl  ow conditions in vitro. This inhibitory eff  ect of 
Eap is specifi  c and cannot be attributed to a nonspecifi  c eff  ect 
of the cationic charge of Eap.
Inhibition of T cell recruitment and delayed type 
hypersensitivity (DTH) responses in vivo by Eap
To test whether Eap aff  ects T cell–mediated immune re-
sponses in vivo, the ability of Eap to interfere with T cell 
  recruitment and cellular immunity was assessed in a DTH 
model. DTH responses are mediated by infi  ltrating T cells in 
response to formerly encountered antigens, resulting in a spe-
cifi  c infl  ammation at the site of local challenge. Mice immu-
nized with oxazolone at day 0 and challenged locally on the 
right ear on day 5 developed a signifi  cant DTH response as 
measured by ear swelling at day 6 (Fig. 4). Mice treated sys-
temically with either purifi  ed or recombinant Eap on day 5 
(3 h before local challenge) had a signifi  cantly reduced DTH 
Figure 2.  Eap inhibits T cell–endothelial cell interactions. (A) The 
adhesion of T cells to TNF-α prestimulated HUVEC (10 ng/ml, 16 h) is 
shown in the absence or presence of blocking mAb against VLA-4, block-
ing mAb against LFA-1, blocking mAb against Mac-1 (each at 20 μg/ml) 
(white bars), increasing concentrations of purifi  ed Eap (gray bars), recom-
binant Eap (black bars) or cationic BSA (20 μg/ml; white bars). (B) SDF-
1α–stimulated transendothelial migration of T cells is shown in the 
absence (white bars) or presence of blocking mAb against VLA-4, blocking 
mAb against LFA-1, blocking mAb against Mac-1 (each at 20 μg/ml) 
(white bars), increasing concentrations of purifi  ed Eap (gray bars), recom-
binant Eap (black bars), or cationic BSA (20 μg/ml; white bars). Cell 
  adhesion and cell transmigration is expressed relative to control (in the 
absence of competitor). Data are mean ± SD (n = 3) of a typical 
  experiment; similar results were obtained in three separate experiments.988  INHIBITION OF EAE BY EAP | Xie et al.
response as compared with vehicle-treated but immunized 
control mice (Fig. 4 A). The eff  ect of Eap was dose depen-
dent and a signifi  cant decrease in ear thickness was observed 
with 40 and 100 μg of purifi  ed Eap/mouse (P < 0.017 and 
P < 0.025, respectively) (Fig. 4 A).
We examined whether Eap reduced DTH by blocking 
the local T cell infi  ltration into the challenged ear. Swollen 
ear tissues were extracted and homogenized, and equal 
amounts of tissue lysates were subjected to Western blot anal-
ysis for the detection of CD3. As shown in Fig. 4 B, Eap 
  inhibited the recruitment of T cells as indicated by the signifi  -
cant decrease in detection of CD3 as compared with vehicle-
treated mice. A major component of the DTH response 
leading to the ear swelling and the local edema is the in-
creased vascular permeability that also promotes the increased 
transmigration and recruitment of lymphocytes. We there-
fore investigated whether Eap treatment reduced the plasma 
leakage into the infl  amed ear by comparing the amounts of 
Evan’s blue dye extracted from the ears of the mice treated 
with Eap or vehicle. The nonchallenged contralateral ears 
were used as control to determine the baseline of Evan’s blue 
leakage. Eap treatment signifi  cantly reduced Evan’s blue 
leakage by 50–60% compared with the vehicle-treated 
  control (Fig. 4 C). Furthermore, Eap largely prevented 
TNF-α–induced increased permeability of an endothelial 
monolayer, as well as the TNF-α–induced morphological 
changes in the interendothelial junctions (unpublished data).
Figure 3.  Effect of Eap on T cell–endothelial cell interactions 
  under physiologic fl  ow conditions. T cells were drawn across TNF-α–
stimulated endothelial monolayers (25 ng/ml, 4 h) under laminar shear 
fl  ow conditions (0.76 dynes/mm2). (A) The adhesion of T cells was studied 
without (white bar) or with purifi  ed Eap (gray bar) or anti–LFA-1 mAb 
(dotted bar) (each 20 μg/ml). (B) The transmigration of T cells was studied 
without (white bar) or with cationic BSA (diagonally striped bar), purifi  ed 
Eap (gray bar), recombinant Eap (black bar), or anti–LFA-1 mAb (dotted 
bar) (each 20 μg/ml). T cell adhesion (A) and transmigration relative to 
control (B) were determined as described in Materials and methods. Data 
are mean ± SEM, n = 3 separate experiments. *, P < 0.05.
Figure 4.  Inhibition of DTH response by Eap. (A) Mice were immu-
nized with OXA (day 0) and at day 5 mice were challenged with local ap-
plication of OXA on the ear. 2 h before local challenge, mice were treated 
without (white bar) or with increasing concentrations of purifi  ed Eap 
(gray bars), recombinant Eap (50 μg, black bar), or cationic BSA (100 μg, 
diagonally striped bar) administered intraperitoneally (n = 5 mice/group). 
Ear thickness was measured after 24 h. The difference in the ear thickness 
in mm is shown. Data are mean ± SD (n = 7). (B) The detection of infi  l-
trated T cells is shown by detection of CD3 in Western blot. Ear tissues 
from DTH-induced mice that were treated with buffer or Eap were 
homogenized and the whole tissue lysates were subjected to Western blot 
to detect the amount of CD3. A typical Western blot for CD3 from the 
ears of buffer- or Eap-treated mice without (−) or with (+) local chal-
lenge using OXA is shown. (C) The vascular leakage (as assessed by infl  ux 
of Evan’s blue) of nonchallenged (white bars) or OXA challenged (black 
bars) ears is shown in mice pretreated with buffer (n = 5) or with Eap 
(n = 5). Ear tissue was removed, dried, and formamide was added to the 
dried ear tissue to extract Evan’s blue; the optical density was registered 
at 590 nm, as a measure for the content of leaked Evan’s blue. Plasma 
leakage is shown as percent of control (nonchallenged ear of buffer-
treated mice) and data are mean ± SD (n = 5). *, P < 0.03.JEM VOL. 203, April 17, 2006  989
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Prevention of EAE by Eap
Our data up to this point indicate that Eap inhibits T cell 
  recruitment in vitro and in vivo. We therefore tested whether 
Eap could be used as a therapy in the EAE model. EAE is 
mediated by autoreactive T cells infi  ltrating the CNS. EAE 
was induced as described in Materials and methods and the 
average onset of the clinical symptoms defi  ning the disease 
occurred on day 12 after immunization of C57BL/6 mice 
with myelin oligodendrocyte glycoprotein (MOG) peptides. 
To determine whether Eap prevents the development of 
EAE, we treated the immunized mice on days 11, 14, and 17 
with purifi  ed or recombinant Eap. We tested 10, 25, and 
50 μg concentrations of Eap administered on days 11, 14, and 
17. Only a subtle reduction of EAE was achieved with 10 μg 
Eap; however, this reduction was not signifi  cant (diff  erence 
in mean cumulative disease score, P = 0.4). In mice that 
  received 25 μg of Eap, we observed an amelioration of EAE 
from day 18 (i.e., 1 d after completing the treatment on day 
17), which remained obvious during the whole course of the 
experiment (diff   erence in mean cumulative disease score, 
P = 0.002). More strikingly, mice that received 50 μg Eap 
only marginally developed EAE, with the mean clinical score 
not exceeding 1 at any time. The prevention of EAE devel-
opment by 50 μg Eap was maintained throughout the study 
period (diff  erence in mean cumulative disease score, P < 
0.001) (Fig. 5 A). In addition, EAE was ameliorated by 50 μg 
of recombinant Eap (diff  erence in mean cumulative disease 
score, P < 0.001) (Fig. 5 B). In contrast, cationic BSA did 
not aff  ect the course of EAE, thus excluding a nonspecifi  c 
  eff  ect of the cationic charge of Eap (Fig. 5 B).
However, in a clinical setting of MS, therapeutic inter-
vention is started after the onset of the disease. Hence, the 
effi   cacy of Eap treatment for EAE was tested under such 
conditions. Strikingly, intervention with Eap after the onset 
of EAE on days 15, 17, and 19 (after initial immunization 
by MOG peptide) resulted in a prompt clinical recovery 
from EAE, which was signifi  cant even 2 d after the fi  rst Eap 
administration (day 17, P < 0.032). Interestingly, the re-
covery from EAE was sustained until the end of the study 
(day 33, P < 0.008) (Fig. 5 C). Overall, the mean cumula-
tive disease score of Eap-treated mice was signifi  cantly 
lower than that of vehicle-treated mice (P < 0.001). In ad-
dition, consistent with our data and with the dramatic in-
hibitory eff  ect on the clinical EAE symptoms by Eap, we 
found that mononuclear cell infi  ltrates were strongly re-
duced or almost absent in the brains of Eap-treated mice 
compared with the vehicle-treated mice that presented with 
perivascular and parenchymal infl  ammatory cell infi  ltrates 
(Fig. 6). Furthermore, the T cell recruitment to the brain 
was inhibited by Eap as indicated by the signifi  cant decrease 
in staining for CD3 in the brains of Eap-treated mice as 
compared with the brains of vehicle-treated mice (Fig. 6). 
Collectively, Eap prevented the development of EAE, as 
well as reverted the disease after its onset as a result of the 
propensity of the protein to block the infi  ltration of infl  am-
matory T cells into the brain.
D  I  S  C  U  S  S  I  O  N 
MS and its mouse counterpart, EAE, is a devastating disease 
with a very high mortality rate (17, 18). The infl  ammatory 
process associated with MS and EAE involves autoreactive 
T cells and additional cells of the immune system that infi  ltrate 
the CNS as well as the breakdown of the BBB (19). These 
Figure 5.  Inhibition of EAE by Eap. MOG-mediated EAE response in 
mice receiving different treatments. (A) Mice were treated with buffer 
(closed diamonds) or increasing concentrations of purifi  ed Eap (10 μg; 
open triangles; 25 μg; closed squares; 50 μg, open diamonds) that were 
administered on days 11, 14, and 17 (arrows) (n = 5–8 mice/group). 
(B) Mice were treated with buffer (open squares), recombinant Eap (50 μg, 
closed triangles), or cationic BSA (50 μg, closed squares) that were 
  administered on days 11, 14, and 17 (arrows) (n = 5 mice/group). (C) Puri-
fi  ed Eap (50 μg, open triangles) was administered on days 15, 17, and 19 
(arrows) (i.e., after the onset of EAE; n = 5 mice/group). Data are repre-
sented as the mean clinical score and are mean ± SEM.990  INHIBITION OF EAE BY EAP | Xie et al.
events are coordinated by chemokines and cytokines as well 
as by adhesion molecules expressed by both the immune cells 
and the activated endothelium, especially involving the VLA-
4–VCAM-1 and the LFA-1–ICAM-1 adhesion systems (20). 
The need of therapies for MS and EAE particularly targeting 
adhesion molecules to limit T cell homing is growing, espe-
cially after the withdrawal of natalizumab, an antibody against 
VLA-4 that demonstrated encouraging effi   cacy in ameliorat-
ing clinical relapses of MS (9). The design of such therapies has 
to be specifi  c in targeting to increase effi   cacy and reduce the 
risk of potential side eff  ects. Our present work clearly demon-
strates that the potent antiinfl  ammatory S. aureus–derived Eap 
may provide the basis for the development of a promising 
novel therapeutic approach for the treatment of MS.
The following three features concur with a potent inhibi-
tory eff  ect of Eap on T cell recruitment in vitro and in vivo 
to eff  ectively interfere with the development and progression 
of EAE. First, in vitro, purifi  ed and recombinant Eap speci-
fi  cally targeted LFA-1–ICAM-1– but not VLA-4–VCAM-1–
mediated T cell recruitment. Consistent with a stronger 
involvement of the latter adhesion pathway in T cell adhe-
sion to endothelial cells and of the former with T cell tran-
sendothelial migration (7, 8, 14, 16), we observed a strong 
inhibitory eff  ect of Eap on T cell transendothelial migration 
as opposed to a weak inhibitory eff  ect on T cell adhesion to 
endothelial cells under physiologic fl  ow conditions. Second, 
in vivo, we found that purifi  ed and recombinant Eap blocked 
T cell recruitment and the consequent clinical responses to 
exogenous antigen in the DTH model. Our data in this 
model are consistent with a previous report by Lee et al. (21); 
although in that report, Eap was administered during both 
the induction and eff  ector phases, whereas in our study ad-
ministration of Eap during the eff  ector phase was suffi   cient 
to block DTH. Moreover, we demonstrate here that Eap 
  reduced the vascular permeability that occurred during the 
infl  ammatory response in DTH. Third, Eap prevented the 
development of EAE and markedly reduced infi  ltration of 
immune cells to the CNS. Strikingly, intervention with Eap 
after the onset of EAE clinical symptoms eff  ectively sup-
pressed EAE and reversed the clinical symptoms almost com-
pletely. Interestingly, the inhibitory eff  ect of Eap on EAE 
persisted even after Eap was discontinued, whereas  “rebound” 
Figure 6.  Eap inhibits the infi  ltration of the CNS by infl  ammatory 
cells during EAE. Histology (hematoxylin and eosin staining; A–D) and 
immunohistology (E–F) from brain sections of EAE mice. Typical photo-
micrographs indicating parenchymal (A) or perivascular (B) infl  ammatory 
cell infi  ltration in the CNS of buffer-treated mice during EAE. The arrows 
indicate the infl  ammatory cell infi  ltrates. No parenchymal or perivascular 
cell infi  ltration was noted in Eap-treated mice (C and D). Massive T cell 
infi  ltrates were noted in the brains of buffer-treated mice as indicated by 
the CD3 staining (E), whereas CD3-positive cells were hardly present in 
the brains of Eap-treated mice (F).JEM VOL. 203, April 17, 2006  991
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elevated EAE symptoms were observed after stopping ad-
ministration of the antibody against VLA-4 (22). The inhibi-
tory eff  ects of Eap could not be attributed to its cationic 
charge because cationic BSA was not eff  ective in any of the 
experimental systems used in our study.
Our fi  nding that Eap blocks the LFA-1–ICAM-1 system 
as a therapeutic modality for EAE are in line with the delay 
of EAE onset by anti–LFA-1 or anti–ICAM-1 antibodies (5, 
6). In contrast, ICAM-1–defi  cient mice exhibited enhanced 
EAE symptoms (23). A similar controversy has also been 
  reported for PECAM-1–defi  cient mice, which were shown 
to have an earlier onset of EAE (24). Thus, besides diff  er-
ences in the animal strains and the experimental models used 
that may account for these discrepancies, it is clear that thera-
peutic studies may not correspond to studies with genetically 
  manipulated mice.
Our data support the conclusion that Eap blocks EAE 
through interfering with the LFA-1–ICAM-1 adhesion path-
way that mediates T cell recruitment most likely as a result of 
its inhibitory eff  ect on transendothelial migration. Consistent 
with our fi  ndings, Laschinger et al. (8) demonstrated that en-
cephalitogenic T cells use LFA-1 for transendothelial migra-
tion but not for adhesion to spinal cord microvessels in vivo. 
However, during the course of EAE, migration of immune 
cells to the CNS takes place in two phases (25). In the fi  rst 
phase, newly emigrated T lymphocytes recognize their anti-
gen and trigger the infl  ammatory response, which leads to 
initiation of the second phase, during which the infl  ammation-
dependent breakdown of the BBB and the intense secondary 
infi  ltration of other infl  ammatory cells such as macrophages 
is prominent (26). Activated T cells with a TH1 cytokine pro-
fi  le are central in coordinating these processes (27). This in-
fl  ammatory response also involves the enhanced expression 
of adhesion molecules on the endothelial cells closely related 
to the damage of the BBB (28). As the LFA-1–ICAM-1 
  adhesion pathway mediates this secondary infl  ammatory cell 
recruitment in part, we speculate that Eap interferes with this 
process and thus accounts for the strong Eap-induced sup-
pression of EAE, even after its onset. However, most studies 
to date have focused on the adhesive events regulating the 
infi  ltration of encephalitogenic T cells, although interfering 
with this secondary infl  ammatory response may be a more 
feasible therapeutic approach in a clinical setting where MS is 
diagnosed after its onset.
The LFA-1–ICAM-1 interaction is also involved in the 
antigen presentation process (29, 30, 31). However, our data 
demonstrate a therapeutic eff  ect of Eap given during the 
  eff  ector phase of EAE and suppressing EAE after its onset. 
This indicates that, in our study, Eap cannot interfere with 
the induction phase to inhibit early interactions between 
  immunocompetent cells after exposure to antigen. However, 
from a (patho-)biologic point of view, it would be intriguing 
to test whether Eap interferes with antigen presentation. The 
underlying mechanisms of the immunomodulatory role of 
Eap (13, 21) will be addressed in detail in future studies. Here, 
the recent crystallographic analysis of Eap revealed structural 
similarity to bacterial superantigens (32) that should also be 
taken into account as well.
The endothelium as an essential architectural component 
of the BBB plays a crucial role in CNS infl  ammation. Under 
physiological conditions, the BBB limits the infi  ltration of 
infl  ammatory cells to the CNS. However, the breakdown of 
the BBB is a hallmark in the development of EAE and MS, 
thereby potentiating the infl  ammatory response (33). Inter-
estingly, we observed that Eap may reduce the TNF-α–
  induced disruption of endothelial cell contacts and the 
consequent increase in endothelial permeability in vitro (un-
published data) as well as the barrier dysfunction and plasma 
leakage in the DTH response in vivo. One could assume that 
Eap might also have a protective eff  ect on the BBB during 
the course of EAE that may very well contribute to and 
  account for its excellent therapeutic effi   cacy.
The advantages of the use of Eap as an antiadhesive treat-
ment of EAE and MS may be manifold. One advantage is 
that Eap targets endothelial ICAM-1, which is up-regulated 
on the infl   amed endothelium during the EAE (34, 35), 
whereas antibodies against VLA-4 target a constitutively 
  expressed integrin on the lymphocytes as well as other types 
of leukocytes. Moreover, Eap seems to interfere specifi  cally 
with LFA-1–ICAM-1–mediated transendothelial migration, 
which is downstream of the VLA-4–VCAM-1–mediated ini-
tial adhesion of encephalitogenic T cells. Another advantage 
is that Eap reversed EAE after its onset, whereas application 
of anti–VLA-4 prevented or ameliorated EAE only if it was 
initiated before the onset of disease and treatment with anti-
VLA-4 during acute disease exacerbated EAE (36). A third 
advantage is that Eap may exert more benefi  cial eff  ects as 
it may interfere with the infl  ammatory cell recruitment sec-
ondary to the infi  ltration of encephalitogenic T cells and may 
protect BBB breakdown. Together, our present work clearly 
demonstrates that Eap may prove a novel and promising ther-
apy for the treatment of MS.
MATERIALS AND METHODS
Mice and cell culture. Female C57BL/6 mice were obtained from The 
Charles River Wiga and housed in the animal facilities of the University of 
Heidelberg. Mice were used between 10 and 12 wk of age. All animal stud-
ies were approved by the governmental offi     ce in Karlsruhe, Germany. 
  HUVECs were cultivated in endothelial cell culture media from PromoCell 
as described previously (37). In experiments performed under fl  ow condi-
tions, HUVECs were isolated and cultured as described previously (15), and 
CD3+ T cells were isolated from sodium-citrated anticoagulated whole 
blood drawn from healthy volunteers as described previously (15). Informed 
consent for blood donations was provided according to the Declaration of 
Helsinki and according to the Brigham and Women’s Hospital Institutional 
Review Board–approved protocols for protection of human subjects.
Reagents. The following reagents were provided by the following 
sources: blocking mAb 6S6 against β1-chain (CD29) (Chemicon); block-
ing mAb LPM19c against Mac-1 (Acris); and mAb HP2.1 against integrin 
α4-chain, (Immunotech). Blocking mAb against LFA-1, L15 was provided 
by Y. van Kooyk (VU University Medical Center, Amsterdam, The Neth-
erlands). Recombinant ICAM-1 and VCAM-1, TNF-α were obtained from 
R&D Systems. FITC-conjugated mAb to human CD3 for fl  ow   cytometry 
was obtained from BD Biosciences. Rat anti–mouse CD3 (MCA1477) 992  INHIBITION OF EAE BY EAP | Xie et al.
for Western blot and immunostaining as well as stromal cell–derived 
  factor-1α (SDF1α) were obtained from Serotec. Cationic BSA was pur-
chased from Sigma-Aldrich.
Eap purifi  cation. Eap from S. aureus strain Newman was purifi  ed as de-
scribed previously with modifi  cations (13). In brief, bacteria were harvested 
after a 20-h incubation in BHI medium (4 × 500 ml) at 37°C. The resultant 
1-M lithium chloride-treated extract was dialyzed against PBS, concentrated, 
and adsorbed onto SP Sepharose (GE Healthcare) in loading buff  er (30 mM 
phosphate buff  er, pH 7.0, 200 mM NaCl) at 4°C overnight. After stepwise 
elution with increasing NaCl concentrations, the pooled eluted fractions 
(between 0.6 and 0.8 M NaCl) were dialyzed against 1:4 diluted PBS at 
4°C and concentrated using Millipore centricon centrifugal fi  lter devices 
(MWCO 30 kD; Millipore). The rententate (containing 2 mg/ml Eap) was 
further purifi  ed by cation exchange chromatography on Mono S 10/100 GL 
tricorn column using an ÄKTA fast performance liquid chromatography 
  system (GE Healthcare), operated with 10 mM Tris/HCl, pH 8.0, and an 
increasing linear NaCl gradient (0–1 M NaCl). Eap-containing fractions 
were purifi  ed on a Superdex 75 HR 10/30 gel fi  ltration column and equili-
brated with TBS at pH 7.4, and Eap-positive fractions were pooled, concen-
trated by ultrafi  ltration (1–1.5 mg/ml), sterile fi  ltered, and snap frozen 
at −80°C until further use. Eap revealed a single protein at 64 kD upon 
SDS-PAGE and was devoid of detectable endotoxin.
Expression and purifi   cation of recombinant Eap. A designer gene 
fragment encoding the entire predicted mature form of Eap from S. aureus 
strain Mu50 was PCR amplifi  ed from genomic DNA using oligonucleotides 
to append SalI and NotI sites at its 5′ and 3′ ends, respectively. The ampli-
fi  ed product was digested with the appropriate restriction endonucleases, 
subcloned into the corresponding sites of the prokaryotic expression vector 
pT7HMT (38), and sequenced in its entirety to confi  rm the integrity of the 
Eap coding region.
After sequencing, the Eap expression plasmid was transformed into 
Escherichia coli strain BL21 (DE3) and the resulting strain was cultured, 
induced, harvested, and lysed under denaturing conditions according to 
  published protocols (38). After centrifugation (25,000 g for 30 min at 20°C), 
the clarifi  ed extract from 1 L of original culture was applied to a 7.5-ml 
column of chelating sepharose fast fl  ow (GE Healthcare) that had been 
previously charged with Ni2SO4 and equilibrated at 20°C in denaturing 
wash buff  er (20 mM NaH2PO4, pH 6.0, 500 mM NaCl, 20 mM imidazole, 
8 M urea). Once the entire sample had entered the column, contaminating 
proteins were washed away with 75 ml of denaturing wash buff  er and the 
specifi  cally bound proteins were eluted with 15 ml of a similar buff  er con-
taining 200 mM imidazole. The denatured, purifi  ed Eap was refolded by 
rapid dilution into 150 ml of native binding buff  er as described previously 
(20 mM Tris, pH 8.0, 0.5 M NaCl; reference 38). Then, the refolded 
  recombinant Eap was concentrated by application to an identical chelating 
column equilibrated at 4°C in native binding buff  er. Once the entire sam-
ple had entered, the column was washed with 75 ml of native binding buf-
fer and the bound proteins were eluted with 15 ml of a similar buff  er 
containing 500 mM imidazole.
After initial purifi  cation, the vector-encoded affi   nity tag was proteolyti-
cally removed from Eap by digestion with recombinant Tobacco Etch Virus 
protease as described previously (38). Once digestion was complete (as judged 
by SDS-PAGE), the entire proteolysis reaction was buff  er exchanged into 
20 mM ethanolamine, pH 9.0, using a HiPrep 26/10 Desalting column (GE 
Healthcare). Untagged Eap was separated from the residual protease and affi   n-
ity tagged by cation-exchange chromatography on a 6-ml Resource S column 
(GE Healthcare), where the bound proteins were resolved by gradient elution 
to 1 M NaCl in ethanolamine buff  er over 60 ml. The fi  nal purity of Eap was 
estimated at >95% (as judged by SDS-PAGE) with a yield of  15 mg Eap 
per liter of original culture. Purifi  ed Eap was buff  er exchanged into double-
deionized water, lyophilized, and stored at −80°C before reconstitution. The 
fi  nal Eap protein contained the additional residues Gly-Ser-Thr at its amino 
terminus as a result of the subcloning and proteolysis procedures.
Preparation of PBT cells. Human PBMCs were isolated from heparin 
anticoagulated blood from healthy donors by Histopaque-1107 (Sigma-
  Aldrich) density gradient centrifugation. PBT cells were separated and puri-
fi  ed from PBMCs using Pan-T cells isolation kit obtained from Miltenyi 
Biotec. The purity of T cells was shown to be >97% measured as CD3 
  positive using fl  ow cytometry.
PBT adhesion to endothelial cells and transendothelial migration 
under static conditions. Adhesion of PBT cells to immobilized ICAM-1 
or VCAM-1 or to cultured monolayers of HUVECs prestimulated for 16 h 
with TNF-α was tested as described previously (37, 39). In brief, plates were 
coated with ICAM-1 or VCAM-1 (10 μg/ml each) in PBS for 16 h at 4°C. 
HUVECs were grown to confl  uency onto 96-well plates and were stimu-
lated for 16 h with TNF-α, and medium was changed before the addition of 
PBT cells. Fluorescently labeled PBT cells (105/well) were washed twice and 
added to the ICAM-1– or VCAM-1–coated wells or to HUVECs and were 
incubated at 37°C for 60 min in the absence or presence of inhibitors. After 
washing, adhesion of PBT cells was quantifi  ed using a fl  uorescence micro-
plate reader (Bio-Tek).
Transendothelial migration was performed as described previously (39). 
In brief, transmigration assays were performed using 6.5-mm transwell fi  lters 
with a 5-μm pore size (Corning Costar). After inserts were coated with gela-
tine (Sigma-Aldrich), HUVECs were seeded onto transwell fi  lters 2 d before 
the assay and grown without medium in the lower compartment for 48 h 
in a humidifi  ed atmosphere (37°C, 5% CO2). At the beginning of the trans-
migration assay, 600 μl migration assay medium (serum-free RPMI 1640 in 
the absence or presence of SDF1α) was added to the lower compartment of 
the transwell system. PBT cells (3 × 105 in 100 μl) were added to the upper 
compartment on top of the endothelial monolayer. After incubation for 4 h 
at 37°C the number of transmigrated cells in the lower compartment was 
  estimated with a cell-counter (CASY-Counter; Schärfe-System). The inserts 
were washed twice in PBS and fi  xed with methanol, stained with crystal vio-
let, and mounted on glass slides to confi  rm the confl  uence of the endothelial 
monolayer of the fi  lters after the assay.
PBT adhesion and transmigration assays under physiological fl  ow 
conditions. Glass coverslips (25-mm dia, Carolina Biological Supply) were 
coated with 2.5 μg/ml of ICAM-1 or VCAM-1 and 2 μg/ml of stromal 
cell-derived factor-1α (CXCL12, SDF-1α)(Peprotech). SDF-1α pretreat-
ment has been shown to promote T cell adhesion to the integrin ligands 
(14). Where indicated, coverslips were treated with purifi  ed Eap, recombi-
nant Eap, or cationic BSA or T cells were treated with function-blocking 
anti–LFA-1 mAb (TS1/22; American Type Culture Collection). PBT cell 
interactions with immobilized ICAM-1 or VCAM-1 were examined under 
conditions of fl  uid shear stress in a parallel plate fl  ow chamber as described 
previously (40). In brief, PBT cells were drawn through the chamber at 
  decreasing fl  ow rates corresponding to an estimated shear stress of 1 dyne/cm2, 
0.76 dynes/cm2, and 0.5 dynes/cm2. T cell accumulation was determined 
after the initial minute of each fl  ow rate by counting the number of cells in 
four diff  erent fi  elds. T cell interactions with substrates were recorded using 
a 20× phase contrast objective, videomicroscopy, and VideoLab software. 
For PBT cell adhesion to HUVECs and transendothelial migration, confl  u-
ent HUVECs grown on 25-mm dia glass coverslips coated with 5 μg/ml 
fi  bronectin (Sigma-Aldrich) were stimulated with TNF-α (25 ng/ml) for 
4 h and inserted into the fl  ow chamber. Where indicated, HUVECs were 
treated with 20 μg/ml Eap. Lymphocytes (106/ml) suspended in fl  ow buf-
fer (Dulbecco phosphate-buff  ered saline/0.1% human serum albumin) were 
drawn across HUVECs at 0.76 dyne/cm2 for 3 min, followed by buff  er 
alone for 10 min. HUVEC monolayers were incubated with 50 ng/ml of 
SDF-1α during 15 min before assay to promote T-lymphocyte TEM (14, 
41). Live-cell imaging of leukocyte TEM was performed using a digital im-
aging system coupled to a Nikon TE2000 inverted microscope as described 
previously (15). Sequential images of diff  erential interference contrast (DIC) 
were taken every 15 s for 10 min in a representative fi  eld from 3 min after 
the start of leukocyte perfusion. The total number of accumulated leukocytes JEM VOL. 203, April 17, 2006  993
ARTICLE
was determined by counting total adherent and transmigrated cells in fi  ve 
fi  elds. The percentage of TEM = total transmigrated leukocytes/(total ad-
hered + transmigrated leukocytes) × 100. P ≤ 0.05 was considered sta-
tistically signifi  cant using the paired Student’s t test or one-way analysis of 
variance for multiple groups.
DTH responses. Mice were sensitized by topical application of a 2% 
  oxazolone (4-ethoxymethylene-2-phenyl-2-oxazoline-5-one; OXA; Sigma-
Aldrich) solution in acetone/olive oil (4:1 vol/vol) onto the shaved abdo-
men (50 μl) (day 0). On day 5, the right ears were challenged by topical 
application of 10 μl of a 1% oxazolone solution on both sides of the ear, 
whereas the left ears were treated with vehicle alone. 3 h before local chal-
lenge, mice were treated with diff  erent concentrations of purifi  ed or recom-
binant Eap administered intraperitoneally. Ear thickness was measured after 
24 h (day 6) using a spring-loaded micrometer (Mitutoyo). Measurement of 
ear thickness was performed by a researcher who was not aware of the treat-
ment groups. The ear swelling was calculated by the diff  erence in the thick-
ness between right ears (OXA treated) and left ears (vehicle treated).
For the detection and quantifi  cation of CD3, ear tissues from DTH-
  induced mice were homogenized and equal amounts of tissue lysates were 
subjected to SDS-PAGE. Western blot analysis with antibody MCA1477 
was performed to detect CD3.
Measurement of vascular leakage. Vascular leakage was measured as 
  described previously (42). DTH-induced mice were injected intracardially 
with 100 μl Evan’s blue dye (30 mg/kg) 24 h after OXA challenge. After 
10 min, mice were killed and ear tissues were removed, dried at 55°C over-
night, and weighed. Evan’s blue was extracted from the dried ear tissue by 
incubation in formamide for 48 h and absorbance was measured at 590 nm 
in a microplate reader (BIO-TEK).
Induction of EAE. MOG p35–55, M  E  V  G  W  Y  R  S  P  F  S  R  V  V  H  L  Y  R  N  G  K  , 
was purchased from TebuBio. Mice were immunized with 200 μg MOG 
peptide emulsifi   ed in Freund’s incomplete adjuvant (Sigma-Aldrich) to-
gether with 5 mg/ml Mycobacterium tuberculosis H37RA (Difco). A total of 
100 μl emulsion was subcutaneously injected into four sites on the fl  anks of 
mice near the tail. At days 0 and 2 after the initial peptide injections, animals 
received additional injections of 400 ng pertussis toxin (Difco) intraperitone-
ally. Diff  erent concentrations of purifi  ed or recombinant Eap or cationic 
BSA in 400 μl PBS (or the same volume of vehicle) were administered 
  intraperitoneally at the times indicated in the fi  gure legends.
Mice were scored daily for clinical assessment of disease based on the 
following criteria: 0, normal; 1, limp tail or hind limb weakness; 2, limp tail 
and hind limb weakness; 3, partial hind limb paralysis; 4, complete hind limb 
paralysis; and 5, moribund or dead. Food and water was made accessible to 
immobile animals, and moribund animals with a score of 5 were killed. 
A score of 5 was not included in the calculation of daily mean clinical score. 
Clinical scoring was performed by a researcher who was not aware of the 
treatment groups.
For the histological and immunohistological analysis of the CNS in the 
EAE model, mice brains were snap frozen in liquid nitrogen and embedded 
in OCT compound. Specimens were cut into 3-μm cross sections. To eval-
uate CNS infi  ltrates, sections were stained with hematoxylin and eosin or 
anti-CD3 mAb followed by eosin counterstaining.
Statistical analysis. For the analysis of the eff  ect of Eap on the DTH   response, 
one-way analysis of variance with Holm-Sidak post-hoc analysis (α value was 
set to 0.05) was performed. For the analysis of the eff  ect of Eap on EAE, the 
Mann-Whitney U test was used for comparison between groups. Statistical 
analysis was performed by using SigmaStat3.1 (Systat Software Inc.).
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